NKCFO LLC’s AbbVie ABBV Stock Holding History

NKCFO LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-885	Closed	-$141K	–	87
2023 Q1	$141K	Hold	885	–	–	0.07%	62
2022 Q4	$143K	Buy	885 +150	+20%	+$23K	0.07%	64
2022 Q3	$99K	Hold	735	–	–	0.05%	64
2022 Q2	$113K	Buy	735 +150	+26%	+$22.9K	0.04%	68
2022 Q1	$95K	Buy	+585	New	+$85K	0.03%	93

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NKCFO LLC's ABBV Position: Q2 2023 in Review

NKCFO LLC sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 885 shares — an estimated $141K sold.

NKCFO LLC first reported a position in ABBV in Q1 2022 and held it in 5 quarters. The position peaked at $143K in Q4 2022. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

NKCFO LLC reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
NKCFO LLC sold 885 AbbVie shares in Q2 2023, an estimated $141K.
NKCFO LLC first reported a position in AbbVie in Q1 2022 and held it in 5 quarters.
NKCFO LLC's AbbVie position peaked at $143K in Q4 2022.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on NKCFO LLC's 13F filing for Q2 2023, filed 2 Aug 2023.